Danielle Watson

HeartSciences (NASDAQ:HSCS)

Heart disease is a global pandemic affecting 26 million worldwide and increasing in prevalence. More effective front-line tools are needed to identify patients earlier while lowering costs for health systems. Current conventional ECG/EKG testing, the key front-line tool, has significant limitations for detecting 2 out of 3 categories of heart disease, ischemia (CAD) and structural heart disease. HeartSciences sits at the forefront of innovation and technological development focused on advancing the field of electrocardiology to provide early heart disease detection. WHO IS HEARTSCIENCES: • HeartSciences seeks to bridge today's "diagnostic gap" in cardiac care by providing effective front-line solutions that assist in the detection of heart disease in at-risk patients. • HeartSciences has invested heavily in research and development focused on advancing the field of electrocardiography through the use of technology to develop new algorithms focused on detecting cardiac conditions not previously available in ECG devices. • Its first product, the MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device, is a resting 12-lead electrocardiograph that uses AI and continuous wavelet transform (CWT) signal processing to provide cardiac information associated with left ventricular diastolic dysfunction (LVDD), a condition which has previously not been possible to detect using conventional electrocardiology. LVDD is associated with almost all forms and co-morbidities of heart disease and may include hypertension, diabetes, valvular disease, ischemia, and reduced systolic function, among others.